Fig. 1From: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trialsOverall survival by RMH score Hazard Ratio = 2.0 (0.9, 4.6) for 1, 2 vs. 0. “Inconclusive” results. Overall survival by for 0–2 prior therapies median was 24 months and for those with >2 prior therapies was 8 monthsBack to article page